Dimebon improves learning in animals with experimental Alzheimer's disease

被引：57

作者：

Lermontova, NN ^{[1
]}

Lukoyanov, NV ^{[1
]}

Serkova, TP ^{[1
]}

Lukoyanova, EA ^{[1
]}

Bachurin, SO ^{[1
]}

机构：

[1] Russian Acad Sci, Inst Physiol Act Subst, Neurochem Lab, Chernogolovka 142432, Moscow Region, Russia

来源：

BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE | 2000年 / 129卷 / 06期

基金：

俄罗斯基础研究基金会;

关键词：

dimebon; H-1 receptor inhibitor; tacrine; AF64A; avoidance conditioning; rats;

D O I：

10.1007/BF02434871

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Systemic administration of antihistamine drug dimebon improves active avoidance conditioning in rats with chronic partial deprivation of cerebral cholinergic functions caused by intracerebroventricular injections of AF64A. The effects of dimebon on learning are similar to those of tacrine used in the treatment of Alzheimer's disease.

引用

页码：544 / 546

页数：3

共 14 条

[1]

BURES J, 1983, TECHNOLOGIES BASIC E

[2]

CACABELOS R, 1994, DRUGS TODAY, P259

[3]

Dringenberg HC, 1998, J NEUROCHEM, V70, P1750

[4] Effects of AF64A on gene expression of choline acetyltransferase (ChAT) in the septo-hippocampal pathway and striatum in vivo [J].

Fan, QI ;

Hanin, I .

NEUROCHEMICAL RESEARCH, 1999, 24 (01) :15-24

[5]

FISHER A, 1982, J PHARMACOL EXP THER, V222, P140

[6] The histamine H-1-antagonist chlorpheniramine facilitates learning in aged rats [J].

Frisch, C ;

Hasenohrl, RU ;

Huston, JP .

NEUROSCIENCE LETTERS, 1997, 229 (02) :89-92

[7] The AF64A model of cholinergic hypofunction: An update [J].

Hanin, I .

LIFE SCIENCES, 1996, 58 (22) :1955-1964

[8] EFFECT OF CHOLINERGIC DEFICIT INDUCED BY ETHYLCHOLINE AZIRIDINIUM (AF64A) ON NORADRENERGIC AND DOPAMINERGIC PARAMETERS IN RAT-BRAIN [J].

HORTNAGL, H ;

POTTER, PE ;

HANIN, I .

BRAIN RESEARCH, 1987, 421 (1-2) :75-84

[9] Effects of tacrine on deficits in active avoidance performance induced by AF64A in rats [J].

Lermontova, N ;

Lukoyanov, N ;

Serkova, T ;

Lukoyanova, E ;

Bachurin, S .

MOLECULAR AND CHEMICAL NEUROPATHOLOGY, 1998, 33 (01) :51-61

[10]

Mashkovskii M. D., 1993, DRUGS, V1, P353

← 1 2 →